Circulating RNA and miRNA in Blood: Potential Applications as Tumor Markers

China Biotechnology

2009, Vol. 29

Issue (11): 94-101 DOI:

Circulating RNA and miRNA in Blood: Potential Applications as Tumor Markers

QI Peng,GAO Chun-fang

Department of Laboratory Medicine, Eastern Hepatobiliary Hospital, The Second Military Medical University of Chinese PLA, Shanghai 200438, China

Download:

HTML

PDF(451KB) HTML
Export: BibTeX | EndNote (RIS)

Abstract

Circulating nucleic acids (CNAs) are extracellular nucleic acids found in cell-free serum, plasma and other body fluids from healthy subjects as well as in patients. The ability to detect and quantitate specific DNA and RNA sequences has opened up the possibility of diagnosis and monitoring of diseases, especially in the field of cancer. Furthermore, in some recent studies it has been suggested a kind of non-coding RNA—microRNA (miRNA), also exist in cell-free serum and plasma, highlighting the field of using CNAs to diagnose cancer. As a novel tumor marker, tumor-specific circulating miRNAs holds great promise in early diagnosis of cancer．

Key words： Circulating RNA MicroRNA Serum Plasma Tumor marker Diagnosis

Received: 12 August 2009 Published: 07 December 2009

ZTFLH:

Q819

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CU Feng
	GAO Chun-Fang

Cite this article:

CU Feng, GAO Chun-Fang. Circulating RNA and miRNA in Blood: Potential Applications as Tumor Markers. China Biotechnology, 2009, 29(11): 94-101.

URL:

https://manu60.magtech.com.cn/biotech/ OR https://manu60.magtech.com.cn/biotech/Y2009/V29/I11/94


［1］	Leon S A, Shapiro B, Sklaroff D M, et al. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res, 1977, 37: 646~650

［2］	Stroun M, Anker P, Beljanski M, et al. Presence of RNA in the nucleoprotein complex spontaneously released by human lymphocytes and frog auricles in culture. Cancer Res, 1978, 38: 3546~3554

［3］	Rosi A, Guidoni L, Luciani A M, et al. RNAlipid complexes released from the plasma membrane of human colon carcinoma cells. Cancer Lett, 1988, 39: 153~160

［4］	Wieczorek A J, Sitaramam V, Machleidt W, et al. Diagnostic and prognostic value of RNAproteolipid in sera of patients with malignant disorders following therapy: first clinical evaluation of a novel tumor marker. Cancer Res, 1987, 47: 6407~6412

［5］	Kopreski M S, Benko F A, Kwak L W, et al. Detection of tumor messenger RNA in the serum of patients with malignant melanoma. Clin Cancer Res, 1999, 5: 1961~1965

［6］	Chen X Q, Bonnefoi H, Pelte M F, et al. Telomerase RNA as a detection marker in the serum of breast cancer patients. Clin Cancer Res, 2000, 6: 3823~3826

［7］	Dasí F, Lledó S, GarcíaGranero E, et al. Realtime quantification in plasma of human telomerase reverse transcriptase (hTERT) mRNA: a simple blood test to monitor disease in cancer patients. Lab Invest, 2001, 81: 767~769

［8］	Silva J M, Dominguez G, Silva J, et al. Detection of epithelial messenger RNA in the plasma of breast cancer patients is associated with poor prognosis tumor characteristics. Clin Cancer Res, 2001, 7: 2821~2825

［9］	Kopreski M S, Benko F A, Gocke C D. Circulating RNA as a tumor marker: detection of 5T4 mRNA in breast and lung cancer patient serum. Ann N Y Acad Sci, 2001, 945: 172~178

［10］	Gal S, Fidler C, Lo Y M, et al. Detection of mammaglobin mRNA in the plasma of breast cancer patients. Ann N Y Acad Sci, 2001, 945: 192~194

［11］	Fleischhacker M, Beinert T, Ermitsch M, et al. Detection of amplifiable messenger RNA in the serum of patients with lung cancer. Ann N Y Acad Sci, 2001, 945: 179~188

［12］	Hasselmann D O, Rappl G, Rssler M, et al. Detection of tumorassociated circulating mRNA in serum, plasma and blood cells from patients with disseminated malignant melanoma. Oncol Rep, 2001, 8: 115~118

［13］	Lo K W, Lo Y M, Leung S F, et al. Analysis of cellfree EpsteinBarr virus associated RNA in the plasma of patients with nasopharyngeal carcinoma. Clin Chem, 1999, 45: 1292~1294

［14］	Ng E K, Tsui N B, Lam N Y, et al. Presence of filterable and nonfilterable mRNA in the plasma of cancer patients and healthy individuals. Clin Chem, 2002, 48: 1212~1217

［15］	Rieber M, Bacalao J. An “external” RNA removable from mammalian cells by mild proteolysis. Proc Natl Acad Sci U S A, 1974, 71: 4960~4964

［16］	Kawamura M T, Paschoal M E, Da Costa Carvalho M D. In vitro interaction of serum protein with circulating DNA of lung cancer patient. Int J Mol Med, 1999, 4: 187~190

［17］	Hasselmann D O, Rappl G, Tilgen W, et al. Extracellular tyrosinase mRNA within apoptotic bodies is protected from degradation in human serum. Clin Chem, 2001, 47: 1488~1489

［18］	Gupta A K, Holzgreve W, Huppertz B, et al. Detection of fetal DNA and RNA in placentaderived syncytiotrophoblast microparticles generated in vitro. Clin Chem, 2004, 50: 2187~2190

［19］	Halicka H D, Bedner E, Darzynkiewicz Z. Segregation of RNA and separate packaging of DNA and RNA in apoptotic bodies during apoptosis. Exp Cell Res, 2000, 260: 248~256

［20］	Ziegler A, ZangemeisterWittke U, Stahel R A. Circulating DNA: a new diagnostic gold mine? Cancer Treat Rev, 2002, 28: 255~271

［21］	Rappl G, Hasselmann D O, Rssler M, et al. Detection of tumorassociated circulating mRNA in patients with disseminated malignant melanoma. Ann N Y Acad Sci, 2001, 945: 189~191

［22］	Miura N, Shiota G, Nakagawa T, et al. Sensitive detection of human telomerase reverse transcriptase mRNA in the serum of patients with hepatocellular carcinoma. Oncology, 2003, 64: 430~434

［23］	ElHefnawy T, Raja S, Kelly L, et al. Characterization of amplifiable, circulating RNA in plasma and its potential as a tool for cancer diagnostics. Clin Chem, 2004, 50: 564~573

［24］	Dasi F, MartínezRodes P, March J A, et al. Realtime quantification of human telomerase reverse transcriptase mRNA in the plasma of patients with prostate cancer. Ann N Y Acad Sci, 2006, 1075: 204~210

［25］	Miura N, Maeda Y, Kanbe T, et al. Serum human telomerase reverse transcriptase messenger RNA as a novel tumor marker for hepatocellular carcinoma. Clin Cancer Res, 2005, 11: 3205~3209

［26］	Funaki N O, Tanaka J, Itami A, et al. Detection of colorectal carcinoma cells in circulating peripheral blood by reverse transcriptionpolymerase chain reaction targeting cytokeratin20 mRNA. Life Sci, 1997, 60: 643~652

［27］	Silva J M, Rodriguez R, Garcia J M, et al. Detection of epithelial tumour RNA in the plasma of colon cancer patients is associated with advanced stages and circulating tumour cells. Gut, 2002, 50: 530~534

［28］	Wong S C, Lo S F, Cheung M T, et al. Quantification of plasma betacatenin mRNA in colorectal cancer and adenoma patients. Clin Cancer Res, 2004, 10: 1613~1617

［29］	Li Y, Elashoff D, Oh M, et al. Serum circulating human mRNA profiling and its utility for oral cancer detection. J Clin Oncol, 2006, 24: 1754~1760

［30］	LagosQuintana M, Rauhut R, Lendeckel W, et al. Identification of novel genes coding for small expressed RNAs. Science, 2001, 294: 853~858

［31］	Qi P, Han J X, Lu Y Q, et al. Virusencoded microRNAs: future therapeutic targets? Cell Mol Immunol, 2006, 3: 411~419

［32］	戚鹏，韩金祥，鲁艳芹. 疱疹病毒编码的miRNAs的研究进展. 中国生物工程杂志, 2006, 26: 69~74 Qi P, Han J X, Lu Y Q. China Biotechnology, 2006, 26: 69~74

［33］	Liu C G, Calin G A, Meloon B, et al. An oligonucleotide microchip for genomewide microRNA profiling in human and mouse tissues. Proc Natl Acad Sci USA, 2004, 101: 9740~9744

［34］	Lu J, Getz G, Miska E A, et al. MicroRNA expression profiles classify human cancers. Nature, 2005, 435: 834~838

［35］	Jiang J, Lee EJ , Gusev Y, et al. Realtime expression profiling of microRNA precursors in human cancer cell lines. Nucleic Acids Res, 2005, 33: 5394~5403

［36］	戚鹏，高春芳. miRNA在肝细胞癌中的研究进展. 中国生物工程杂志, 2008, 28: 94~101 Qi P, Gao C F. China Biotechnology, 2008, 28: 94~101

［37］	EsquelaKerscher A，Slack F J．OncomirsmicroRNAs with a role in cancer. Nat Rev Cancer, 2006, 6: 259~269

［38］	Lawrie C H, Gal S, Dunlop H M, et al. Detection of elevated levels of tumourassociated microRNAs in serum of patients with diffuse large Bcell lymphoma. Br J Haematol, 2008, 141: 672~675

［39］	Mitchell P S, Parkin R K, Kroh E M, et al. Circulating microRNAs as stable bloodbased markers for cancer detection. Proc Natl Acad Sci USA, 2008, 105: 10513~10518

［40］	Wong T S, Liu X B, Wong B Y, et al. MaturemiR184 as potential oncogenic microRNA of squamous cell carcinoma of tongue. Clin Cancer Res, 2008, 14: 2588~2592

［41］	Wang K, Zhang S, Marzolf B, et al. Circulating microRNAs, potential biomarkers for druginduced liver injury. Proc Natl Acad Sci U S A, 2009, 106:4402~4407

［42］	Ng E K, Chong W W, Jin H, et al. Differential expression of microRNAs in plasma of colorectal cancer patients: A potential marker for colorectal cancer screening, 2009,58:1375~1381

［43］	Chen X, Ba Y, Ma L, et al. Characterization of miRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res, 2008, 18: 997~1006

［44］	Chim S S, Shing T K, Hung E C, et al. Detection and Characterization of Placental MicroRNAs in Maternal Plasma. Clin Chem, 2008, 54:482~490

［45］	Gilad S, Meiri E, Yogev Y, et al. Serum microRNAs are promising novel biomarkers. PLoS ONE, 2008, 3: e3148

［46］	Poon L L, Leung T N, Lau T K, et al. Presence of fetal RNA in maternal plasma. Clin Chem, 2000, 46: 1832~1834

［47］	Ng E K, Tsui N B, Lau T K, et al. mRNA of placental origin is readily detectable in maternal plasma. Proc Natl Acad Sci U S A, 2003, 100: 4748~4753

［48］	Ng E K, Leung T N, Tsui N B, et al. The concentration of circulating corticotropinreleasing hormone mRNA in maternal plasma is increased in preeclampsia. Clin Chem, 2003, 49: 727~731

［49］	Tsui N B, Chim S S, Chiu R W, et al. Systematic microarraybased identification of placental mRNA in maternal plasma: towards noninvasive prenatal gene expression profiling. J Med Genet, 2004, 41: 461~467

［50］	Oudejans C B, Go A T, Visser A, et al. Detection of chromosome 21encoded mRNA of placental origin in maternal plasma. Clin Chem, 2003, 49: 1445~1449

［51］	Wataganara T, LeShane E S, Chen A Y, et al. Plasma gammaglobin gene expression suggests that fetal hematopoietic cells contribute to the pool of circulating cellfree fetal nucleic acids during pregnancy. Clin Chem, 2004, 50: 689~693

［52］	Hunter M P, Ismail N, Zhang X, et al. Detection of microRNA expression in human peripheral blood microvesicles. PLoS ONE, 2008, 3: e3694

［53］	Rabinowits G, GerelTaylor C, Day J M, et al. Exosomal microRNA: a diagnostic marker for lung cancer. Clin Lung Cancer, 2009, 10: 42~46

［54］	Valadi H, Ekstrm K, Bossios A, et al. Exosomemediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol, 2007, 9: 654~659

［55］	Taylor D D, GercelTaylor C. MicroRNA signatures of tumorderived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol, 2008, 110: 13~21

[1]	MA Qiao-ni,WANG Meng,ZHU Xing-quan. Research Advances in Recombinase-aided Amplification Technology and Its Application in Rapid Detection of Pathogenic Microorganisms[J]. China Biotechnology, 2021, 41(6): 45-49.

[2]	CHEN Yu-qiong,TAN Wen-hua,LIU Hai-feng,CHEN Gen. Protective Effect of miR-29a on Lipopolysaccharide-induced Human Pulmonary Microvascular Endothelial Cells Injury by Targeting PTEN Expression[J]. China Biotechnology, 2021, 41(5): 8-16.

[3]	SHI Zhong-lin,CUI Jun-sheng,YANG Ke,HU An-zhong,LI Ya-nan,LIU Yong,DNEG Guo-qing,ZHU Can-can,ZHU Ling. Research Progress in Isothermal Amplification of Nucleic Acid Based on Microfluidic Chip[J]. China Biotechnology, 2021, 41(2/3): 116-128.

[4]	FAN Yue-lei,WANG Yue,WANG Heng-zhe,LI Dan-dan,MAO Kai-yun. *Research Progress of in Vitro* Diagnostic Technologies for SARS-CoV-2**[J]. China Biotechnology, 2021, 41(2/3): 150-161.

[5]	LI Bo,WANG Ze-jian,LIANG Jian-guang,LIU Ai-jun,LI Hai-dong. Breeding of High-yield Rifamycin SV Strain by Plasma Action Combined with Oxygen Restriction Model[J]. China Biotechnology, 2021, 41(2/3): 38-44.

[6]	ZHAO Ping,YANG Yan-ping. Patent Situation Analysis of Diagnosis Technology for Coronavirus Infection in Human[J]. China Biotechnology, 2020, 40(1-2): 51-56.

[7]	HU Yan,LI Hui,HE Cheng-wen,ZHU Jing,XIE Zhi-ping. Construction of a Yeast Strain for the Evaluation of Subcellular Fractionation[J]. China Biotechnology, 2020, 40(10): 10-23.

[8]	MEI Ya-xian,WANG Yue,LUO Wen-xin. Application of Nano-antibody in the Prevention, Diagnosis and Treatment of Infectious Diseases[J]. China Biotechnology, 2020, 40(10): 24-34.

[9]	Pan-hong ZHANG,Lian-lian LI,Xiu-mei ZHANG,Jia-jun CUI,Yin-jie JIANG. Advances in the Relationship Between microRNA and Chemotherapy Resistance of Lung Cancer[J]. China Biotechnology, 2019, 39(7): 79-84.

[10]	Zuo-bo XU,Jiu-bing LI,Hong-lei DING. *Research Progress in Mycoplasma hyopneumonia* Detection Technology**[J]. China Biotechnology, 2019, 39(4): 78-83.

[11]	Lin YANG,Yong-chao LI,Teng-hua ZHANG,Yi-xiao DENG,Jin YANG,Zhi-bo GAO. Comprehensive Evaluation is needed for Precision Diagnosis in Cancer Immunotherapies[J]. China Biotechnology, 2019, 39(2): 62-73.

[12]	Zhou TONG,Jing-hua YAN. Progress in Non-structural Protein 1 (NS1) Based Diagnosis of Flaviviruses Infection[J]. China Biotechnology, 2019, 39(2): 82-89.

[13]	SHEN Bing-lei,WANG Yu-xuan,HAN Shuo,LI Xi,YANG Zhuo-ni-na,ZOU Zi-wen,LIU Juan. Research Progress of Non-coding RNA in Autophagy[J]. China Biotechnology, 2019, 39(12): 56-63.

[14]	LIU Li-ping, ZHANG Chun, YIN Shuang, WANG Qi, ZHANG Yao, YU Rong, LIU Yong-dong, SU Zhi-guo. Design, Preparation, Characterization and Preliminary Evaluation of an Albumin Binding Peptide-Doxorubicin Conjugate[J]. China Biotechnology, 2017, 37(4): 68-75.

[15]	Huan XIAO,Zong NING. The Application of Oxidized Graphene Fluorescence in Biomedical Field[J]. China Biotechnology, 2017, 37(12): 84-89.

Viewed

Full text

Abstract

Cited

Shared

Discussed